PTPRC and neoplasm: Indeed, detection of CTCs by EpCAM/DAPI-positive selection and CD45-negative staining identified CTC clusters for 50 (primary disease) to 67% (recurrent tumor) of the 54 patients explored, with a correlation to platinum-resistance [74].